Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug TAK-505 enters first human trials

NCT ID NCT07436728

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach, colorectal, lung, or head and neck cancers, will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TAK-505
What this could lead to
If successful, this could point toward a new treatment option for certain advanced solid tumors like stomach, colorectal, lung, or head and neck cancers.
What could go wrong
This is an early first-in-human trial, so the drug may not work or could have unexpected side effects. The results are preliminary and may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer gastric adenocarcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMORS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Baylor College of Medicine

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Cleveland Clinic Foundation

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • H Lee Moffitt Cancer Center

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

  • Icahn School of Medicine at Mount Sinai

    NOT_YET_RECRUITING

    New York, New York, 10029, United States

  • MD Anderson

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75230, United States

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Sarah Cannon Research Institute SCRI

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seattle Cancer Care Alliance

    NOT_YET_RECRUITING

    Seattle, Washington, 98109, United States

  • Tennessee Oncology

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

  • UCI Health

    NOT_YET_RECRUITING

    Orange, California, 92868, United States

  • Univeristy of Minnesota

    NOT_YET_RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • University of California San Diego Medical Center, La Jolla

    NOT_YET_RECRUITING

    San Diego, California, 92093, United States

  • University of California San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.